medigraphic.com
Academia Mexicana de Neurología, A.C.

2014, Number 6

<< Back Next >>

Rev Mex Neuroci 2014; 15 (6)

A critical appraisal of guidelines for the diagnosis and treatment of Parkinson’s disease

Cervantes-Arriaga A, Martínez-Ramírez D, Llorens-Arenas R, Rodríguez-Violante M, Leal OR, Estrada-Bellmann R, Velázquez-Osuna S, León-Jiménez C, Morales-Briceño HH, Neri-Nani G, López-Ruiz M

Language: Spanish
References: 41
Page: 335-344
PDF size: 163.22 Kb.


ABSTRACT

Background: Clinical practice guidelines are documents used for decision-making in patient clinical care and even for health-policy development. We consider the assessment of their methodological quality is essential.
Objetive: To assess the methodological quality of the most recent evidence-based guidelines for the diagnosis and treatment of Parkinson’s disease.
Methods: We conducted a systematic review of guidelines on Parkinson’s disease published from June 2008 to June 2014. Eligible guidelines were critically evaluated by different reviewers using the Appraisal of Guidelines Research and Evaluation II (Appraisal of Guidelines for Research and Evaluation II, AGREE II).
Results: A total of 26 references were obtained, from where 16 were eligible for critical evaluation. A total of 14 guidelines were considered scientifically admissible. Overall, the domain of applicabilityobtained the lowest scores. Top rated domain was clarity of presentation.SIGN and NICE guidelines were scored higher among all evaluated guidelines.
Conclusion: A large number of guidelines were deemed admissible, however most of them require an update. The methodological quality of the guidelines varies widely, so it is suggested that developers guide agencies adhere to accepted methodological standards including the AGREE II instrument.


REFERENCES

  1. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-22. Cervantes-Arriaga A, et al. Evaluación de guías de Parkinson Rev Mex Neuroci Noviembre-Diciembre, 2014; 15(6): 335-344 343

  2. Diaz NL, Waters CH. Current strategies in the treatment of Parkinson’s disease anda a personalized approach to management. Expert Rev Neurother 2009; 9: 1781-9.

  3. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. Clin Orthop Relat Res 2007; 455: 3-5.

  4. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18-23.

  5. Sabharwal S, Patel V, Nijjer SS, Kirresh A, Darzi A, Chambers JC, et al. Guidelines in cardiac clinical practice: evaluation of their methodological quality using the AGREE II instrument. J R Soc Med 2013; 106: 315-22.

  6. Holmer HK, Ogden LA, Burda BU, Norris SL. Quality of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. PloS One 2013; 8: e58625.

  7. Esandi ME, Ortiz Z, Chapman E, Dieguez MG, Mejía R, Bernztein R. Production and quality of clinical practice guidelines in Argentina (1994-2004): a cross-sectional study. Implement Sci 2008; 3: 43.

  8. Abarshi E, Rietjens J, Caraceni A, Payne S, Deliens L, Van Den Block L. Towards a standarised approach for evaluating guidelines and guidance documents on palliative sedation: study protocol. BMC Palliat Care 2014; 13: 34.

  9. Potter M, Gordon S, Hamer P. The nominal group technique: A useful consensus methodology in physiotherapy. NZ J Phyisother 2004; 32: 126-30.

  10. Glaser EM. Using behavioral science startegies for defining the Stateof- the-Art. J Applied Behav Sci 1980; 16: 79-92.

  11. Kramer MS, Feinstein AR. Clinical Biostatistics: The biostatistics of concordance. Clin Pharmacol Ther 1981; 29: 111-123.

  12. Fleiss JL. Measuring nominal scale agrrement among many raters. Psychol Bull 1971; 76: 378-82.

  13. Diagnóstico y tratamiento de la enfermedad de Parkinson inicial y avanzada en el tercer nivel de atención. México: Secretaría de Salud; 2010.

  14. Diagnóstico y tratamiento de la enfermedad de Parkinson inicial en el primer nivel de atención. México: Secretaría de Salud; 2008.

  15. Macphee GJ, Chaudhuri KR, David AS, Worth P, Wood B. Managing impulse control behaviours in Parkinson’s disease: practical guidelines. Br J Hosp Med (Lond) 2013; 74: 160-6.

  16. Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W, et al. Canadian Guidelines on Parkinson’s disease. Can J Neurol Sci 2012; 39: S1-30.

  17. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 924-31.

  18. Carr J, Kies B, Fine J. Movement Disorders Group of South Africa. Guideline for the treatment of Parkinson’s disease. S Afr Med J 2009; 99: 755-6.

  19. Silberstein P, Bittar RG, Boyle R, Cook R, Coyne T, O’Sullivan D, et al. Deep brain stimulation for Parkinson’s disease: Australian referral guidelines. J Clin Neurosci 2009; 16: 1001-8.

  20. Grupo de Cirugía Funcional Sociedad Española de Neurocirugía (SENEC); Grupo de Trastornos del Movimiento Sociedad Española de Neurología (SEN). Documento de Consenso sobre la estimulación cerebral profunda en la enfermedad de Parkinson. Rev Neurol 2009; 49(6): 327-31.

  21. Mariscal A, Medrano IH, Cánovas AA, Lobo E, Loinaz C, Vela L, et al. Manejo perioperatorio de la enfermedad de Parkinson. Neurologia 2012; 27(1): 46-50.

  22. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 2013; 20: 16-34.

  23. Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Early (uncomplicated) Parkinson’s disease. Vol. 1. 2nd Ed. In: Gilhus NE, Barnes MP (eds.). Brainin. European Handbook of Neurological Management. Blackwell Publishing; 2011, p. 217-36.

  24. Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Late (complicated) Parkinson’s disease. Vol. 1. 2nd Ed. In: Gilhus NE, Barnes MP. (eds.). Brainin. European Handbook of Neurological Management. Blackwell Publishing, 2011, p. 237-67.

  25. Parkinson’s disease: National clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians. National Institute for Health and Care Excellence, 2006, reviewed 2011.

  26. Diagnosis and pharmacological management of Parkinson’s disease. A national clinical guideline. Scottish Intercollegiate Guidelines Network-National Government Agency; 2010.

  27. Fox SH, Katzenschlager R, Lim S, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society Evidence-Based medicine review update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011; 26: S1-41.

  28. Seppi K, Weintraub D, Coehlo M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society Evidence- Based medicine review update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011; 26: S42-80.

  29. Jackson R, Feder G. Guidelines for clinical guidelines. Br Med J 1998; 317: 427-8.

  30. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg 2011; 128: 305-10.

  31. Shekelle PG, Ortiz E, Rhodes S, Morton SC, Eccles MP, Grimshaw JM, et al. Validity of Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA 2001; 286: 1461-7.

  32. Grol R, Wensing M. What drives change? Barriers to and incentives for achieving evidence-based practice. Med J 2004; 14: 57-60.

  33. Al-Ansary LA, Tricco AC, Adi Y, Bawazeer G, Perrier L, Al-Ghonaim M, et al. A systematic review of recent clinical practice guidelines on the diagnosis, assessment and management of hypertension. PLoS One 2013; 8: e53774.

  34. Huang TW, Lai JH, Wu MY, Chen SL, Wu CH, Tam KW. Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. BMC Med 2013; 11: 191.

  35. Malheiro R, de Monteiro-Soares M, Hassan C, Dinis-Ribeiro M. Methodological quality of guidelines in gastroenterology. Endoscopy 2014; 46: 513-25. Cervantes-Arriaga A, et al. Evaluación de guías de Parkinson 344 Rev Mex Neuroci Noviembre-Diciembre, 2014; 15(6): 335-344

  36. Sabharwal S, Patel NK, Gauher S, Holloway I, Athanasiou T. High methodologic quality but poor applicability: assessment of the AAOS guidelines using the AGREE II instrument. Clin Orthop Relat Res 2014; 472: 1982-8.

  37. Tudor KI, Kozina PN, Marusic A. Methodological rigour and transparency of clinical practice guidelines developed by neurology professional societies in Croatia. PLoS One 2013; 8: e69877.

  38. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012; 52: 930-45.

  39. Moo-Kyung Oh, Heuisug Jo, You Kyoung Lee. Improving the reliability of clinical practice gudielines appraisals: Effects of the Korean AGREE II scoring guide. J Korean Med Sci; 2014; 29: 771-5.

  40. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 1: performance, usefulness and areas of improvement. CMAJ 2010; 182: 1045-52.

  41. Qaseem A, Forland F, Macbeth F, Ollenschlager G, Phillips S, et al. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med 2012; 156(7): 525-31.




2020     |     www.medigraphic.com